Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Marianna Dávid is active.

Publication


Featured researches published by Marianna Dávid.


Genes, Chromosomes and Cancer | 2013

Multiplex Ligation-Dependent Probe Amplification and Fluorescence In Situ Hybridization are Complementary Techniques to Detect Cytogenetic Abnormalities in Multiple Myeloma

Donát Alpár; Danielle de Jong; Zsofia Holczer-Nagy; Béla Kajtár; Suvi Savola; Pál Jáksó; Marianna Dávid; Szabolcs Kosztolányi; László Kereskai; László Pajor; Karoly Szuhai

Multiple myeloma (MM) is a genetically heterogeneous disease with diverse clinical outcomes. Interphase fluorescence in situ hybridization (i‐FISH) is the most commonly used approach to detect recurrent cytogenetic abnormalities in this malignancy. We aimed to assess the performance of multiplex ligation‐dependent probe amplification (MLPA) to reveal copy number abnormalities (CNAs) in MM. Diagnostic bone marrow samples from 81 patients were analyzed using 42 MLPA probes for the following regions: 1p32‐31, 1p21, 1q21.3, 1q23.3, 5q31.3, 12p13.31, 13q14, 16q12, 16q23, and 17p13. All samples were also screened by i‐FISH for the presence of hyperdiploidy, deletion/monosomy of chromosome 13, deletion of TP53, disruption of the immunoglobulin heavy‐chain gene, t(4;14), t(11;14), t(14;16), t(8;14), gain of 5q and abnormalities of chromosome 1. A total of 245 alterations were detected in 79 cases (98%). Investigating the same aberrations, the two methods showed a congruency of higher than 90%. A low proportion of cells with the relevant abnormality, focal CNAs and unmatched probes were responsible for the discrepancies. MLPA revealed 95 CNAs not detected by i‐FISH providing additional information in 53 cases (65%). Scrutiny of CNAs on chromosome 1, using more than 20 probes, revealed significant heterogeneity in size and location, and variable intra‐chromosomal and intra‐clonal rates of loss or gain. Our results suggest that MLPA is a reliable high‐throughput technique to detect CNAs in MM. Since balanced aberrations are key to prognostic classification of this disease, MLPA and i‐FISH should be applied as complementary techniques in diagnostic pathology.


Pathology & Oncology Research | 2001

New diagnostic tool for differentiation of idiopathic hypereosinophilic syndrome (HES) and secondary eosinophilic states

Timea Berki; Marianna Dávid; Beáta Bóné; Hajna Losonczy; János A. Vass; Péter Németh

The hypereosinophilic syndrome (HES) is a very rare disease, characterized by persistent eosinophilia with tissue involvement and organ dysfunction which often precedes a subsequent T cell lymphoma. Interleukin-5 secreted by a T lymphocyte subpopulation has been described in previous reports as the most important factor responsible for the prolonged lifespan of the eosinophils. The goal of the present study was to describe a fast, simple diagnostic method for the differentiation of HES and secondary eosinophilic states. Beside the surface marker analysis of peripheral blood mononu-clear cells (PBMC) we measured surface bound IgE molecules on lymphocytes and eosinophil cells, intracellular cytokines (IL-5, INFγ) in CD4+ lymphocytes and eosinophil major basic protein (MBP) in eosinophils using flow cytometric detection method. The appearance of an IL-5 producing cell population with a decreased number of INFγ positive lymphocytes was characteristic for the blood samples of HES patients. Predominance of Th2 cells with the appearance of a CD8+/CD3-/CD56+ cell population was restricted for the HES cases and could not be detected in secondary eosinophilic individuals. Our flow cytometric cytokine detection method (with parallel cell surface marker analysis) does not require cell separation or long term cell culture steps previously described for the detection of IL-5 producing cells. Therefore it seems to be a more appropriate approach for the differential diagnosis of primary and secondary eosinophilic states.


Blood | 2007

Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders.

Marianna Dávid; Nicholas C.P. Cross; Sonja Burgstaller; Andrew Chase; Claire Curtis; Raymond Dang; Martine Gardembas; John M. Goldman; Francis H. Grand; George Hughes; Francoise Huguet; Louise Lavender; Grant A. McArthur; Francois Xavier Mahon; Giorgio Massimini; Junia V. Melo; Philippe Rousselot; Robin Russell-Jones; John F. Seymour; Graeme N. Smith; Alastair Stark; Katherine Waghorn; Zariana Nikolova; Jane F. Apperley


Seminars in Thrombosis and Hemostasis | 1991

Effect of pentosan polysulfate on activated partial thromboplastin time, thrombin time, euglobulin clot lysis, and on tissue-type plasminogen activator and plasminogen activator inhibitor activities in patients with thromboembolic disease

Hajna Losonczy; Marianna Dávid; Ibolya Nagy


Orvosi Hetilap | 2010

Risk assessment model for venous thromboembolism in hospitalized surgical and non-surgical patients in the 4th Hungarian Antithrombotic Guidelines entitled “Diminution and Treatment of Venous Thromboembolism”

Marianna Dávid; Hajna Losonczy; Miklós Udvardy; Z. Boda; György Blaskó; Attila Tar; György Pfliegler


Orvosi Hetilap | 2005

I-es típusú antitrombinhiány artériás és vénás thrombosisok hátterében egy súlyosan thrombophiliás családban

Orsolya Tóth; Marianna Dávid; Tamas Habon; Ágnes Nagy; Zsuzsanna Keszthelyi; Norbert Kovács; Hajna Losonczy


Orvosi Hetilap | 1989

[Two cases of Richter's syndrome].

K. Werling; I. Nagy; Hajna Losonczy; Marianna Dávid; Tamás Magyarlaki


Thrombosis Research | 2012

C0078 Dose modifying effect of VKORC1 9041G > A and 6009C > T gene-polimorphisms in acenocoumarol anticoagulated hungarian outpatients

Réka Mózes; Orsolya Tóth; Hajna Losonczy; Marianna Dávid; Barbara Réger; Béla Melegh; Ágnes Nagy


Orvosi Hetilap | 2010

[Questionnaire for assessing the risk of venous thromboembolism in hospitalized surgical and non-surgical patients in the 4th Hungarian antithrombotic guideline entitled "Risk reduction and treatment of venous thromboembolism"].

Marianna Dávid; Hajna Losonczy; Miklós Udvardy; Z. Boda; György Blaskó; Attila Tar; György Pfliegler


Orvosi Hetilap | 2010

Vénásthromboembolia-kockázati kérdoív kórházban kezelt sebészeti és nem sebészeti betegek részére .,A thromboemboliák kockázatá nak csökkentése és kezelése" címu, 4. magyar antithromboticus irányelvben

Marianna Dávid; Hajna Losonczy; Miklós Udvardy; Z. Boda; György Blaskó; Attila Tar; György Pfliegler

Collaboration


Dive into the Marianna Dávid's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Z. Boda

University of Debrecen

View shared research outputs
Top Co-Authors

Avatar

Attila Tar

Boston Children's Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge